Mylan

Viatris Forms Eye Care Unit from Acquisitions

Viatris, formed in November 2020 from the merger of Mylan with Pfizer’s Upjohn division, has established an eye care division following the closure of two acquisitions on Jan. 3.

Upjohn/Mylan Merger Closes to Form Viatris

Pfizer has completed the spin-off of its Upjohn Business and combined it with Mylan to form Viatris, which began trading on Nov. 17. On closure of the deal, Pfizer stockholders owned about 57% of the outstanding shares of Viatris common stock and Mylan shareholders owned roughly 43%.

Mylan Buys Aspen’s European Thrombosis Assets

Mylan has agreed to buy the related intellectual property and commercialization rights of Aspen Pharmacare’s European thrombosis business for €641.9 million. The company will use proceeds from the sale to pay down debt.

Mylan Invests Again in Mapi’s MS Therapy

US generics specialist Mylan is investing an additional $20 million in Mapi Pharma to support the latter’s ongoing Phase 3 clinical study and eventual commercialization of Glatiramer Acetate (GA) Depot for treating patients with relapsing-remitting multiple sclerosis (RRMS) in the US.

Injecting Growth and Innovation

Continuous Processing

Pfizer Merges Upjohn With Mylan

US States Sue Drugmakers Over Price-fixing

DCAT Announces New Board of Directors

FDA Approves Teva’s Generic EpiPen

Pfizer Under Pressure in EpiPen Shortage

Mylan and Fujifilm arm Join up on Biosimilar

FDA Approves Mylan’s Herceptin Biosimilar

Teva Realigns, may Slash 25% of Workforce

Sanofi Charges Mylan With Lantus Breach

Indivior Settles Patent Dispute with Mylan

Mylan Finalizes US EpiPen Settlement

J&J Protests Death Row Use of its Drug

Mylan Faces FTC Investigation on EpiPen

US Senator Urges DoJ to Testify at EpiPen Hearing

Mylan settles US EpiPen Dispute

Mylan CEO to Testify on EpiPen Hikes

Mylan to Buy Sweden’s Meda for $9.9 Billion

Mylan Bid for Perrigo Fails

Court Says Mylan Can Uphold Perrigo Bid

FDA Approves Mylan’s Yasmin Copies

Mylan Makes New Bid for Perrigo

Perrigo Acquires Scar Management Brand

M&A Carousel Turns Faster as Deals Set New Records

Teva to Acquire the Generics Activities of Allergan for Over $40 Billion

US Sandoz Arm Fights US Overpay Lawsuit

Teva and Mylan Slug it out Over Takeover Bid

Perrigo Acquires Patheon's Mexican Operations

Mylan Sweetens its Bid for Perrigo

Mylan Board Unanimously Rejects Teva’s Bid